{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:36:38Z","timestamp":1761748598020,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.acvd.2014.01.011","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T17:01:34Z","timestamp":1394470894000},"page":"188-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice"],"prefix":"10.1016","volume":"107","author":[{"given":"Eric","family":"Bruckert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2014.01.011_bib0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.011_bib0010","first-page":"e6","article-title":"Heart disease and stroke statistics\u00a0\u2013\u00a02013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.011_bib0015","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/eurheartj\/eht356","article-title":"Cardiovascular disease in Europe: epidemiological update","volume":"34","author":"Nichols","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.011_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0025","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in anti-hypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.011_bib0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2012.06.112","article-title":"Relationships between chronic use of statin therapy, presentation of acute coronary syndromes and one-year mortality after an incident acute coronary event","volume":"163","author":"Vervueren","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1475-2840-10-31","article-title":"Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the US diabetic population, 1999\u20132008","volume":"10","author":"Kuznik","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2369-14-132","article-title":"Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001\u20132010","volume":"14","author":"Kuznik","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2796.2006.01730.x","article-title":"Time trends in population cholesterol levels 1986\u20132004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study","volume":"260","author":"Eliasson","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.acvd.2009.02.002","article-title":"Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996\u20132007","volume":"102","author":"Ferrieres","year":"2009","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2014.01.011_bib0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/HJR.0b013e3281764429","article-title":"Trends in cardiovascular risk factor prevalence (1995\u20132000\u20132005) in northeastern Spain","volume":"14","author":"Grau","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.acvd.2014.01.011_bib0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.acvd.2012.11.003","article-title":"Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study","volume":"106","author":"Bongard","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2014.01.011_bib0070","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.011_bib0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000348859","article-title":"Total lipid management and cardiovascular disease in the dyslipidemia international study","volume":"125","author":"Ferrieres","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.acvd.2014.01.011_bib0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0085","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.acvd.2010.04.003","article-title":"Residual dyslipidaemia after statin treatment in France: prevalence and risk distribution","volume":"103","author":"Ferrieres","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2014.01.011_bib0090","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-153-3-201008030-00004","article-title":"Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study","volume":"153","author":"Pletcher","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0100","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.011_bib0105","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acvd.2014.01.011_bib0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jebm.12045","article-title":"The Cochrane Database of Systematic Reviews\u2013Issue 4 2013","volume":"6","year":"2013","journal-title":"J Evidence-Based Med"},{"year":"2011","series-title":"English\/French list of 182 non-governmental organizations in official relations with WHO reflecting decisions of EB128","author":"World Health Organization","key":"10.1016\/j.acvd.2014.01.011_bib0115"},{"key":"10.1016\/j.acvd.2014.01.011_bib0120","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acvd.2014.01.011_bib0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL-cholesterol with statin therapy in people at low-risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.011_bib0130","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.2013.281348","article-title":"Statin therapy for primary prevention of cardiovascular disease","volume":"310","author":"Taylor","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.011_bib0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.011_bib0145","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.acvd.2014.01.011_bib0150","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.011_bib0155","first-page":"146","article-title":"Statin-associated rhabdomyolysis: is there a dose-response relationship?","volume":"27","author":"Holbrook","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0160","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high dosage statin therapy in hyperlipidemic patients\u00a0\u2013\u00a0the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2014.01.011_bib0165","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-511X-11-40","article-title":"Statin therapy, myopathy and exercise\u00a0\u2013\u00a0a case report","volume":"11","author":"Semple","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.acvd.2014.01.011_bib0175","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.acvd.2014.01.011_bib0185","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0190","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.autrev.2013.07.001","article-title":"Statin-induced necrotizing myositis\u00a0\u2013\u00a0a discrete autoimmune entity within the \u201cstatin-induced myopathy spectrum\u201d","volume":"12","author":"Hamann","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.acvd.2014.01.011_bib0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2013.06.008","article-title":"Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins","volume":"81","author":"Lahaye","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.acvd.2014.01.011_bib0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent QTL for GATM expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2014.01.011_bib0205","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1093\/eurheartj\/eht213","article-title":"Beyond statins: what to expect from add-on lipid regulating therapy?","volume":"34","author":"Laufs","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.011_bib0210","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0215","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0220","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0225","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.011_bib0230","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid-lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0235","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid-lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0240","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/phar.1127","article-title":"Aspirin for primary prevention of cardiovascular disease events","volume":"32","author":"Nemerovski","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.acvd.2014.01.011_bib0245","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.thromres.2005.09.013","article-title":"Aspirin overprescription in primary cardiovascular prevention","volume":"118","author":"Manes","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2014.01.011_bib0250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/dc07-9917","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"30","author":"Buse","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2014.01.011_bib0255","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2014.01.011_bib0260","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0270","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1161\/CIRCULATIONAHA.107.695007","article-title":"Risk\/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension","volume":"117","author":"Messerli","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.011_bib0275","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various anti-hypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.011_bib0280","first-page":"CD002003","article-title":"Beta-blockers for hypertension","volume":"11","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acvd.2014.01.011_bib0285","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.011_bib0290","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCOUTCOMES.109.868299","article-title":"The JUPITER trial: results, controversies, and implications for prevention","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.acvd.2014.01.011_bib0295","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrcardio.2013.80","article-title":"Statins in the primary prevention of cardiovascular disease","volume":"10","author":"Reiner","year":"2013","journal-title":"Nat Rev Cardiol"},{"year":"2010","series-title":"Annexes. Efficacit\u00e9 et efficience des hypolipemiants\u00a0: une analyse centr\u00e9e sur les statines","author":"Haute Autorit\u00e9 de sant\u00e9","key":"10.1016\/j.acvd.2014.01.011_bib0300"},{"year":"2014","key":"10.1016\/j.acvd.2014.01.011_bib0305"},{"year":"2013","series-title":"\u00c9valuation des technologies de sant\u00e9: analyse m\u00e9dico-\u00e9conomique. \u00c9valuation par classe des m\u00e9dicaments antihypertenseurs","author":"Haute Autorit\u00e9 de sant\u00e9","key":"10.1016\/j.acvd.2014.01.011_bib0310"},{"key":"10.1016\/j.acvd.2014.01.011_bib0315","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/heartjnl-2013-303698","article-title":"The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?","volume":"99","author":"van Staa","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2014.01.011_bib0320","doi-asserted-by":"crossref","first-page":"d1672","DOI":"10.1136\/bmj.d1672","article-title":"Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis","volume":"342","author":"Greving","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2014.01.011_bib0325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijcard.2013.08.127","article-title":"Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study","volume":"169","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2014.01.011_bib0330","first-page":"851","article-title":"Patients\u2019 and physicians\u2019 perceptions and experience of hypercholesterolaemia: a qualitative study","volume":"53","author":"Durack-Bown","year":"2003","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.acvd.2014.01.011_bib0335","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2004.06.011","article-title":"Impact of physicians\u2019 beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment","volume":"149","author":"Franciosi","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2014.01.011_bib0340","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1345\/aph.1K209","article-title":"Factors related to adherence to statin therapy","volume":"41","author":"McGinnis","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.acvd.2014.01.011_bib0345","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1525-1497.2004.30516.x","article-title":"Suboptimal statin adherence and discontinuation in primary and secondary prevention populations","volume":"19","author":"Ellis","year":"2004","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.acvd.2014.01.011_bib0350","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02849887","article-title":"Medication adherence trends with statins","volume":"22","author":"Huser","year":"2005","journal-title":"Adv Ther"},{"year":"2008","series-title":"ISPOR Medication Compliance and Persistence Special Interest Group","author":"International Society for Pharmaco-economics Outcomes Research","key":"10.1016\/j.acvd.2014.01.011_bib0355"},{"key":"10.1016\/j.acvd.2014.01.011_bib0360","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1592\/phco.2005.25.8.1035","article-title":"Cardiovascular morbidity associated with non-adherence to statin therapy","volume":"25","author":"Blackburn","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.acvd.2014.01.011_bib0365","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clinthera.2011.12.011","article-title":"Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis","volume":"34","author":"Degli Esposti","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.acvd.2014.01.011_bib0370","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/pds.1297","article-title":"Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study","volume":"16","author":"Wei","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2014.01.011_bib0375","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of non-adherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.acvd.2014.01.011_bib0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7812\/TPP\/09-090","article-title":"Patients\u2019 perspectives on non-adherence to statin therapy: a focus-group study","volume":"14","author":"Fung","year":"2010","journal-title":"Perm J"},{"key":"10.1016\/j.acvd.2014.01.011_bib0385","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10557-007-6040-4","article-title":"Predictors of adherence to statins for primary prevention","volume":"21","author":"Mann","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2014.01.011_bib0390","first-page":"e133","article-title":"Primary non-adherence to statin therapy: patients\u2019 perceptions","volume":"19","author":"Harrison","year":"2013","journal-title":"Am J Manag Care"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213614000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213614000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:41:21Z","timestamp":1761745281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213614000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1875213614000278"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2014.01.011","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2014.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}